Skip to Content
Søg Menu
Vi dækker

ECTRIMS | European Committee for Treatment and Research in Multiple Sclerosis

ECTRIMS 2025

Possible Biomarkers for Progression Independent of Relapse Activity Identified in RMS

  • / Jan Andreasen

Cladribine Shows a Robust Safety Profile – Both as First-Line and Subsequent Therapy in MS

/ Jan Andreasen
ECTRIMS25MS
Gloria Dalla Costa

ECTRIMS 2025: Ultra-Processed Food Intake is Linked to Increased MS Disease Activity

/ Gloria Dalla Costa
ECTRIMS25 Play the Video
Linda Forsberg

ECTRIMS 2025: Swedish Real-World MS Data Demonstrates Long-Term Safety and Effectiveness of Cladribine

/ Linda Forsberg
ECTRIMS25MS Play the Video

ECTRIMS 2024

Sahla El Mahdaoui

The effects of anti-CD20 therapy on TFH cells in relapsing-remitting MS

/ Sahla El Mahdaoui
ECTRIMS24MS Play the Video

ECTRIMS 2024: New Data Has the Potential to Paving the Way for More Personalised and Effective Treatment Plans

/ Jan Andreasen
ECTRIMS24MS

Top 4 mest sete MEDtalks fra ECTRIMS 2024

DMTs During Pregnancy in Women with MS Do Not Affect Relapse Rates in Postpartum Periods

/ Neurologi / Lene Von Kappelgaard

Poor Sleep Has a Deleterious Impact on Health-Related Quality of Life in People with MS

/ Neurologi / Martin Langeskov Christensen

New Biomarker and Comorbidity Insights in NMOSD and MOGAD

/ Neurologi / Nasrin Asgari

Nationwide Patient-Reported Outcome Portal for MS is Feasible and Provides Clinical Value

/ Neurologi / Rolf Pringler Holm
Back to top